Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STX-721/PFL-721 in NSCLC with EGFR or HER2 Exon 20 Insertion Mutations
NCT06043817Phase 2Recruiting
- Sponsor
- Pierre Fabre Laboratories
- Start
- Sep 2023
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of PFL-721 in non-small cell lung cancer (NSCLC), sponsored by Pierre Fabre Laboratories. Started Sep 2023; status: recruiting.
02
Drugs
PFL-721
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06043817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06043817.